Skip to content

Study · Animal study (in vivo) · rat · 2020

7 results

Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion.

Kolovrat M, Gojkovic S, Krezic I, Malekinusic D, Vrdoljak B, Kasnik Kovac K, Kralj T, Drmic D, Barisic I, Horvat Pavlov K, Petrovic A, Duzel A and 6 more

Show all authors

Knezevic M, Mirkovic I, Kokot A, Boban Blagaic A, Seiwerth S, Sikiric P

World journal of hepatology1 May 2020Cited by 43 (Europe PMC)

PMID32547687 (opens in a new tab)PMCIDPMC7280862 (opens in a new tab)DOI10.4254/wjh.v12.i5.184 (opens in a new tab)PepBankPUB-32547687
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with the Pringle maneuver, BPC‑157 counteracted electrocardiogram disturbances: increased P wave amplitude, S1Q3T3 QRS pattern and tachycardia.

    In plain wordsIn rats with temporary liver blood-flow blockage, BPC‑157 counteracted heart rhythm changes seen on the ECG.

    Peptide
    BPC-157
    Outcome
    DecreaseElectrocardiogram disturbances (P wave amplitude, S1Q3T3 pattern, tachycardia)
    Study

    ratn: not reported in source

    Pringle maneuver (30 min portal triad clamping, then reperfusion)
    Comparator
    Untreated controls
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 µg, 10 ng/kg · intraperitoneal or bath to the portal triad · single administrationAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 counteracts electrocardiogram disturbances (increased P wave amplitude, S1Q3T3 QRS pattern and tachycardia).
    2 context sentences
    Summary · context
    In deeply anesthetised rats, the portal triad was clamped up for 30 min.
    Summary · context
    Rats then underwent reperfusion for either 15 min or 24 h.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with the Pringle maneuver, BPC‑157 rapidly presented a vascular shunting pathway (portal vein to inferior caval vein) that affected the disturbed haemodynamics.

    In plain wordsIn rats with temporary liver blood-flow blockage, BPC‑157 quickly opened a bypass blood route that helped blood flow.

    Peptide
    BPC-157
    Outcome
    IncreaseCollateral vascular shunting pathway
    Study

    ratn: not reported in source

    Pringle maneuver (30 min portal triad clamping, then reperfusion)
    Comparator
    Untreated controls
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg, 10 ng/kg · intraperitoneal or bath to the portal triad · single administrationAs given in this study (rat).

    Source sentences

    Summary
    Rapidly presented vascular pathway (portal vein-superior mesenteric vein-inferior mesenteric vein-rectal veins-left ileal vein-inferior caval vein) as the adequate shunting immediately affected disturbed haemodynamics.
    2 context sentences
    Summary · context
    In deeply anesthetised rats, the portal triad was clamped up for 30 min.
    Summary · context
    Rats then underwent reperfusion for either 15 min or 24 h.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with the Pringle maneuver, BPC‑157 markedly attenuated portal hypertension during obstruction and completely abrogated portal and caval hypertension in reperfusion.

    In plain wordsIn rats with temporary liver blood-flow blockage, BPC‑157 reduced or removed high pressure in the portal and caval veins.

    Peptide
    BPC-157
    Outcome
    DecreasePortal and caval hypertension
    Study

    ratn: not reported in source

    Pringle maneuver (30 min portal triad clamping, then reperfusion)
    Comparator
    Untreated controls
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 µg, 10 ng/kg · intraperitoneal or bath to the portal triad · single administrationAs given in this study (rat).

    Source sentences

    Summary
    Portal hypertension and severe aortal hypotension during PTO, as well as portal and caval hypertension and mild aortal hypotension in reperfusion and refractory ascites formation were markedly attenuated (during PTO) or completely abrogated (reperfusion)
    2 context sentences
    Summary · context
    In deeply anesthetised rats, the portal triad was clamped up for 30 min.
    Summary · context
    Rats then underwent reperfusion for either 15 min or 24 h.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with the Pringle maneuver, BPC‑157 attenuated severe aortal hypotension during obstruction and abrogated mild aortal hypotension in reperfusion.

    In plain wordsIn rats with temporary liver blood-flow blockage, BPC‑157 reduced or removed low aortic blood pressure.

    Peptide
    BPC-157
    Outcome
    DecreaseAortal hypotension
    Study

    ratn: not reported in source

    Pringle maneuver (30 min portal triad clamping, then reperfusion)
    Comparator
    Untreated controls
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 µg, 10 ng/kg · intraperitoneal or bath to the portal triad · single administrationAs given in this study (rat).

    Source sentences

    Summary
    Portal hypertension and severe aortal hypotension during PTO, as well as portal and caval hypertension and mild aortal hypotension in reperfusion and refractory ascites formation were markedly attenuated (during PTO) or completely abrogated (reperfusion)
    2 context sentences
    Summary · context
    In deeply anesthetised rats, the portal triad was clamped up for 30 min.
    Summary · context
    Rats then underwent reperfusion for either 15 min or 24 h.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with the Pringle maneuver, BPC‑157 attenuated refractory ascites formation during obstruction and abrogated it in reperfusion.

    In plain wordsIn rats with temporary liver blood-flow blockage, BPC‑157 reduced or removed fluid build-up in the abdomen.

    Peptide
    BPC-157
    Outcome
    DecreaseRefractory ascites formation
    Study

    ratn: not reported in source

    Pringle maneuver (30 min portal triad clamping, then reperfusion)
    Comparator
    Untreated controls
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg, 10 ng/kg · intraperitoneal or bath to the portal triad · single administrationAs given in this study (rat).

    Source sentences

    Summary
    Portal hypertension and severe aortal hypotension during PTO, as well as portal and caval hypertension and mild aortal hypotension in reperfusion and refractory ascites formation were markedly attenuated (during PTO) or completely abrogated (reperfusion)
    2 context sentences
    Summary · context
    In deeply anesthetised rats, the portal triad was clamped up for 30 min.
    Summary · context
    Rats then underwent reperfusion for either 15 min or 24 h.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with the Pringle maneuver, BPC‑157 counteracted thrombosis in portal vein tributaries, inferior caval vein and hepatic artery during portal triad obstruction.

    In plain wordsIn rats with temporary liver blood-flow blockage, BPC‑157 counteracted blood clots in nearby veins and the liver artery.

    Peptide
    BPC-157
    Outcome
    DecreaseThrombosis in portal vein tributaries, inferior caval vein and hepatic artery
    Study

    ratn: not reported in source

    Pringle maneuver (30 min portal triad clamping, then reperfusion)
    Comparator
    Untreated controls
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg, 10 ng/kg · intraperitoneal or bath to the portal triad · single administrationAs given in this study (rat).

    Source sentences

    Summary
    thrombosis in portal vein tributaries and inferior caval vein or hepatic artery was counteracted during portal triad obstruction PTO.
    2 context sentences
    Summary · context
    In deeply anesthetised rats, the portal triad was clamped up for 30 min.
    Summary · context
    Rats then underwent reperfusion for either 15 min or 24 h.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with the Pringle maneuver, BPC‑157 counteracted organ injury in lung, liver, intestine, spleen (splenomegaly) and right heart that ischemia and reperfusion produce.

    In plain wordsIn rats with temporary liver blood-flow blockage, BPC‑157 counteracted damage to lung, liver, intestine, spleen and heart.

    Peptide
    BPC-157
    Outcome
    DecreaseOrgan injury in lung, liver, intestine, spleen and right heart
    Study

    ratn: not reported in source

    Pringle maneuver (30 min portal triad clamping, then reperfusion)
    Comparator
    Untreated controls
    Outcome group
    Organ injury · Whole body
    Studied dose
    10 µg, 10 ng/kg · intraperitoneal or bath to the portal triad · single administrationAs given in this study (rat).

    Source sentences

    Summary
    lung pathology (severe capillary congestion), liver (dilated central veins and terminal portal venules), intestine (substantial capillary congestion, submucosal oedema, loss of villous architecture), splenomegaly, right heart (picked P wave values)
    2 context sentences
    Summary · context
    In deeply anesthetised rats, the portal triad was clamped up for 30 min.
    Summary · context
    Rats then underwent reperfusion for either 15 min or 24 h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.